Article
Oncology
Katarina Pinjusic, Olivier Andreas Dubey, Olga Egorova, Sina Nassiri, Etienne Meylan, Julien Faget, Daniel Beat Constam
Summary: This study reveals that Activin-A secretion by melanoma cells inhibits adaptive antitumor immunity by indirectly inhibiting CD8(+) T cell infiltration, regardless of BRAF status. It is also found that Activin-A/INHBA expression is correlated with resistance to anti-PD1 therapy in melanoma patients and impairs response to combination anti-cytotoxic T-Lymphocyte associated protein 4/anti-PD1 treatment in preclinical models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Benjamin Wolfson, Michelle R. Padget, Jeffrey Schlom, James W. Hodge
Summary: This study demonstrates that ER targeting drugs can enhance NK cell killing of ER+ and ER- breast cancer cells, with GPR30 signaling activation playing a key role. The mechanism remains effective in populations resistant to 4-OHT, and in vivo studies show the combination of fulvestrant and N-803 is effective in triple-negative breast cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Hao Chi, Xixi Xie, Yingjie Yan, Gaoge Peng, Dorothee Franziska Strohmer, Guichuan Lai, Songyun Zhao, Zhijia Xia, Gang Tian
Summary: This study established a reliable signature based on genes related to NK cells in HNSCC, providing a new perspective for assessing immunotherapy response and prognosis. The 17-NRGs signature demonstrated excellent predictive performance and offered new perspectives for evaluating pre-immune efficacy, facilitating future precision immuno-oncology research.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Cell Biology
Hongmei Zhang, Yue Zhu, Junli Wang, Sijia Weng, Fengqiong Zuo, Changlong Li, Tongbo Zhu
Summary: Inhibition of PKC iota enhances the susceptibility of PDAC to NK cytotoxicity and reduces the immunosuppressive microenvironment by suppressing PDL1 expression. Co-culture with NK92 further induces PDL1 upregulation, leading to immune escape of PDAC cells. Combining PKC iota inhibitor with PD1/PDL1 blocker significantly boosts the cytotoxicity of NK92 against PDAC cells, showing promise for enhancing PDAC immunotherapy.
CELLULAR SIGNALLING
(2021)
Review
Immunology
Ken Maes, Anna Mondino, Juan Jose Lasarte, Xabier Agirre, Karin Vanderkerken, Felipe Prosper, Karine Breckpot
Summary: Cancer cells can evade the immune system through epigenetic alterations, but epigenetic modulating agents have the potential to restore immunological fitness and overcome peripheral tolerance to transformed cells. By acting on both cancer cells and immune cells, EMAs represent interesting strategies for combinatorial therapies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Changhee Park, Kyeonghun Jeong, Joon-Hyeong Park, Sohee Jung, Jeong Mo Bae, Kwangsoo Kim, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Se-Hoon Lee, Ju-Seog Lee, Dong-Wan Kim, Gyeong Hoon Kang, Doo Hyun Chung, Dae Seog Heo
Summary: The study demonstrated a negative correlation between overall methylation aberrancy and tumor immunogenicity, indicating the importance of methylation aberrancy for tumors to evade immune surveillance. This highlights the need for further development of methylation biomarkers in cancer research.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Oncology
Matteo Caforio, Cristina Sorino, Ignazio Caruana, Gerrit Weber, Antonio Camera, Loredana Cifaldi, Biagio De Angelis, Francesca Del Bufalo, Alessia Vitale, Bianca Maria Goffredo, Rita De Vito, Doriana Fruci, Concetta Quintarelli, Maurizio Fanciulli, Franco Locatelli, Valentina Folgiero
Summary: IDO1 plays a crucial role in immune escape of neuroblastoma, inhibiting the activity of anti-GD2 CAR T cells and NK cells. Combination therapy with IDO1 inhibitors could enhance the long-term efficacy of immunotherapeutic approaches.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Diana C. Lopez, Yvette L. Robbins, Joshua T. Kowalczyk, Wiem Lassoued, James L. Gulley, Markku M. Miettinen, Gary L. Gallia, Clint T. Allen, James W. Hodge, Nyall R. London Jr
Summary: This study comprehensively evaluates the tumor immune microenvironment (TIME) of chordoma using multispectral immunofluorescence (MIF). The results show that myeloid cells significantly infiltrate chordoma tumor parenchyma, while T cells tend to be excluded from the tumor parenchyma and have higher stromal infiltration. This suggests that future immunotherapy strategies for chordoma should aim to decrease myeloid cell suppressive function and enhance cytotoxic T cell and NK cell killing.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Julian A. Marin-Acevedo, ErinMarie O. Kimbrough, Yanyan Lou
Summary: The immune system plays a crucial role in defending against cancer, but tumor cells can evade immune recognition. Immunotherapy enhances host immune response to combat tumors.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Abbass Darwich, Alessandra Silvestri, Mohamed-Reda Benmebarek, Juliette Mouries, Bruno Cadilha, Alessia Melacarne, Lapo Morelli, Domenico Supino, Alexandre Taleb, Hannah Obeck, Claudio Sustmann, Agnese Losurdo, Giovanna Masci, Giuseppe Curigliano, Sebastian Kobold, Giuseppe Penna, Maria Rescigno
Summary: The study found that CHI3L1 in the serum of Trastuzumab-resistant HER2+ patients can inhibit NK cell's ADCC, leading to immune escape in cancer. CHI3L1 hinders the correct polarization of lytic granules, affecting the immune response, and targeting CHI3L1 could enhance therapeutic efficacy in antibody and cell-based immunotherapies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Michael F. Kaminski, Laura Bendzick, Rachel Hopps, Marissa Kauffman, Behiye Kodal, Yvette Soignier, Peter Hinderlie, Joshua T. Walker, Todd R. Lenvik, Melissa A. Geller, Jeffrey S. Miller, Martin Felices
Summary: This study generated a Tri-specific Killer Engager (TriKE) against TEM8, which selectively activates NK cells to kill TEM8-expressing tumor cells and stromal cells, providing a novel anti-tumor, anti-stroma, and anti-angiogenic cancer therapy for patients with solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
David B. Rosen, Anne Mansson Kvarnhammar, Burkhardt Laufer, Thomas Knappe, Jens Jakob Karlsson, Enping Hong, Yu-Chi Lee, Dhruv Thakar, Luis Alejandro Zuniga, Kathy Bang, Simran Singh Sabharwal, Karan Uppal, Janne Damm Olling, Kristian Kjaergaard, Thomas Kurpiers, Meike Schnabel, Diana Reich, Philipp Glock, Joachim Zettler, Mathias Krusch, Ana Bernhard, Stefan Heinig, Valentino Konjik, Thomas Wegge, Yvonne Hehn, Steffen Killian, Laura Viet, Josefine Runz, Frank Faltinger, Mohammad Tabrizi, Kristin Laura Abel, Vibeke Miller Breinholt, Stina M. Singel, Kennett Sprogoe, Juha Punnonen
Summary: Recombinant interleukin-2 (IL-2) is an approved cancer immunotherapy, but it has severe toxicities and suboptimal pharmacokinetics. TransCon IL-2 beta/gamma is a novel prodrug designed to address these issues, showing sustained release of IL-2 and potential antitumor activity in animal models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biotechnology & Applied Microbiology
Peter J. J. Chockley, Jorge Ibanez-Vega, Giedre Krenciute, Lindsay J. J. Talbot, Stephen Gottschalk
Summary: In this study, researchers aimed to enhance the function of CAR immune cells by tuning the CAR immune synapses using an intracellular scaffolding protein binding site. The results showed that the synapse-tuned CAR immune cells exhibited increased effector cell functionality both in vitro and in vivo, leading to enhanced killing of tumor cells.
NATURE BIOTECHNOLOGY
(2023)
Review
Oncology
Farhoodeh Ghaedrahmati, Nafiseh Esmaeil, Maryam Abbaspour
Summary: Natural killer (NK) cells have potential for cancer immunotherapy, but the immunosuppressive tumor microenvironment (TME) hinders their efficacy. Immune checkpoints contribute to NK cell exhaustion and tumor immune escape. Blocking immune checkpoints can rescue exhausted NK cells and enhance their anti-tumor activity. This review focuses on immune checkpoint blockade strategies, particularly using chimeric antigen receptor (CAR)-NK cells, to redirect NK cells to solid tumors.
CANCER COMMUNICATIONS
(2023)
Article
Biochemistry & Molecular Biology
Lucas Henrique Rodrigues da Silva, Luana Correia Croda Catharino, Viviane Jennifer da Silva, Gabriela Coeli Menezes Evangelista, Jose Alexandre Marzagao Barbuto
Summary: Natural killer (NK) cells are innate lymphocytes that play a vital role in immune surveillance against tumors. Various NK-based therapies, including transfer of expanded and activated cells, genetic engineering, cytokine therapy, and tumor-specific antibody-guided cells, are being used in cancer treatment. This article also discusses the potential approaches to control glioblastoma.
Review
Biochemistry & Molecular Biology
Takumi Kobayashi, Stephen R. Mattarollo
MOLECULAR IMMUNOLOGY
(2019)
Article
Dermatology
Paula Kuo, Zewen K. Tuong, Siok Min Teoh, Ian H. Frazer, Stephen R. Mattarollo, Graham R. Leggatt
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2018)
Article
Oncology
Daniel Kerage, Megan S. F. Soon, Brianna L. Doff, Takumi Kobayashi, Michael D. Nissen, Pui Yeng Lam, Graham R. Leggatt, Stephen R. Mattarollo
Article
Oncology
Pui Yeng Lam, Takumi Kobayashi, Megan Soon, Bijun Zeng, Riccardo Dolcetti, Graham Leggatt, Ranjeny Thomas, Stephen R. Mattarollo
CANCER IMMUNOLOGY RESEARCH
(2019)
Article
Integrative & Complementary Medicine
Michael D. Nissen, Esther T. L. Lau, Peter J. Cabot, Kathryn J. Steadman
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
(2019)
Review
Immunology
Daniel Kerage, Erica K. Sloan, Stephen R. Mattarollo, Pamela A. McCombe
JOURNAL OF NEUROIMMUNOLOGY
(2019)
Article
Biochemical Research Methods
Michael D. Nissen, Manabu Kusakabe, Xuehai Wang, Guillermo Simkin, Deanne Gracias, Kateryna Tyshchenko, Ainsleigh Hill, Justin Meskas, Stacy Hung, Elizabeth A. Chavez, Daisuke Ennishi, Tomohiro Aoki, Clementine Sarkozy, Joseph M. Connors, Pedro Farinha, Graham W. Slack, Randy D. Gascoyne, Ryan R. Brinkman, David W. Scott, Christian Steidl, Andrew P. Weng
Article
Oncology
Tomohiro Aoki, Lauren C. Chong, Katsuyoshi Takata, Katy Milne, Monirath Hav, Anthony Colombo, Elizabeth A. Chavez, Michael Nissen, Xuehai Wang, Tomoko Miyata-Takata, Vivian Lam, Elena Vigano, Bruce W. Woolcock, Adele Telenius, Michael Y. Li, Shannon Healy, Chanel Ghesquiere, Daniel Kos, Talia Goodyear, Johanna Veldman, Allen W. Zhang, Jubin Kim, Saeed Saberi, Jiarui Ding, Pedro Farinha, Andrew P. Weng, Kerry J. Savage, David W. Scott, Gerald Krystal, Brad H. Nelson, Anja Mottok, Akil Merchant, Sohrab P. Shah, Christian Steidl
Article
Hematology
Takumi Kobayashi, Pui Yeng Lam, Hui Jiang, Karolina Bednarska, Renee Elyse Gloury, Valentine Murigneux, Joshua Tay, Nicolas Jacquelot, Rui Li, Zewen Kelvin Tuong, Graham R. Leggatt, Maher K. Gandhi, Michelle M. Hill, Gabrielle T. Belz, Shyuan Ngo, Axel Kallies, Stephen R. Mattarollo
Article
Immunology
M. Tran, S. Yoon, M. Teoh, S. Andersen, PY. Lam, B. W. Purdue, A. Raghubar, SJ. Hanson, K. Devitt, K. Jones, S. Walters, J. Monkman, A. Kulasinghe, ZK. Tuong, HP. Soyer, I. H. Frazer, Q. Nguyen
Summary: This study presents an integrated experimental framework and analytical process to study cancer-immune cell communication across the whole tumor section without tissue dissociation. The approach enables the discovery and validation of ligand-receptor interactions, which is crucial for cancer immunotherapy development.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Kef K. Prasit, Laura Ferrer-Font, Olivia K. Burn, Regan J. Anderson, Benjamin J. Compton, Alfonso J. Schmidt, Johannes U. Mayer, Chun-Jen J. Chen, Nathaniel Dasyam, David S. Ritchie, Dale Godfrey, Stephen R. Mattarollo, P. Rod Dundar, Gavin F. Painter, Ian F. Hermans
Summary: In this study, the combination of intratumoural CpG administration and NKT cell agonist alpha-GalCer showed superior efficacy in inducing tumour regression compared to CpG alone. The antitumour effect was mediated primarily by CD8(+) T cells and also resulted in an abscopal effect on distant untreated tumours. This effect was dependent on sustained activity of NKT cells and the infiltration of KLRG1(+) NKT cells. Increased exposure to type I interferon was observed, affecting various immune cell types. Dendritic cell signaling through the type I IFN receptor was found to be crucial for the antitumour response. The addition of tumour-antigen derived peptide conjugated to alpha-GalCer enhanced the antitumour response in less effective tumour models.
Article
Medicine, General & Internal
Arti M. Raghubar, Duy T. Pham, Xiao Tan, Laura F. Grice, Joanna Crawford, Pui Yeng Lam, Stacey B. Andersen, Sohye Yoon, Siok Min Teoh, Nicholas A. Matigian, Anne Stewart, Leo Francis, Monica S. Y. Ng, Helen G. Healy, Alexander N. Combes, Andrew J. Kassianos, Quan Nguyen, Andrew J. Mallett
Summary: This study applied spatial transcriptomics sequencing (ST-seq) to investigate the gene expression patterns in the kidneys of mice and humans. The results revealed the gene expression signatures of different nephron structures and microvascular regions, and identified potential ligand-receptor interactions in specific areas of the kidneys. The study provides valuable insights into the complexity of kidney physiology and serves as a valuable resource for future research in this field.
FRONTIERS IN MEDICINE
(2022)
Meeting Abstract
Immunology
Graham R. Leggatt, Nazhifah Salim, Stephen Mattarollo
JOURNAL OF IMMUNOLOGY
(2020)